How much funding has Tizona Therapeutics raised?

Tizona Therapeutics has raised $370.0M in total funding, most recently a Corporate Round.

Who are Tizona Therapeutics's investors?

Tizona Therapeutics's investors include Gilead Sciences, Canaan Partners, Abingworth Bioventures, MPM Capital, Amgen, Lightstone Ventures.

When was Tizona Therapeutics founded?

Tizona Therapeutics was founded in 2014.

Where is Tizona Therapeutics headquartered?

Tizona Therapeutics is headquartered in South San Francisco, California, United States.

What industry is Tizona Therapeutics in?

Tizona Therapeutics operates in Biotech, Healthcare.

How many employees does Tizona Therapeutics have?

Tizona Therapeutics has 11-50 employees.

Tizona Therapeutics

Improving outcomes for people with cancer

South San Francisco, United States · Founded 2014 · $370.0M raised

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 11–50
Founded: 2014
Business Model: B2B

Website: tizonatx.com
Total Funding: $370.0M
Last Round: $300.0M Corporate RoundJul 2020
Rounds: 3

About

Tizona Therapeutics is a clinical-stage immunotherapy company applying novel scientific insights to change the course of cancer progression and relapse. Founded in 2014 and headquartered in South San Francisco, California, Tizona has advanced two first-in-class immune checkpoint therapeutics into the clinic, with a strategic alliance with Gilead Sciences supporting its lead program TTX-080.

Summary

Tizona Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2014. It has raised $370.0M in total across 3 rounds, most recently a $300.0M Corporate Round round in Jul 2020. Investors include Gilead Sciences, Canaan Partners and Abingworth Bioventures.